B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities

REFERENCES

• DiLillo DJ, Horikawa M, Tedder TF. B-lymphocyte effector functions in health and disease. Immunol Res 2011;49(1–3):281–292.
   Google Scholar
• Efremov DG, Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs 2011;20(5):623–636.
   PubMed Web of Science ®Google Scholar
• Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;31(2):119–132.
   PubMed Web of Science ®Google Scholar
• Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov 2012;11(2):96.
   PubMed Web of Science ®Google Scholar
• Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998;25(1):42–59.
   Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352(8):804–815.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198–206.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219–234.
   PubMed Web of Science ®Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 2002;16(6):1015–1027.
   Web of Science ®Google Scholar
• Seung AH. Standard of care and novel treatments for chronic lymphocytic leukemia. Am J Health Syst Pharm: AJHP. 2010;67(21):1813–1824.
   Google Scholar
• Hainsworth JD, Litchy S, Barton JH, Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol: official journal of the American Society of Clinical Oncology 2003;21(9):1746–1751.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol: official journal of the American Society of Clinical Oncology 2007;25(35):5616–5623.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 2008;111(3):1094–100.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol: official journal of the American Society of Clinical Oncology 2010;28(10):1749–1755.
   PubMed Web of Science ®Google Scholar
• Zent CS, Call TG, Shanafelt TD, Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113(8):2110–2118.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101(1):6–14.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol: official journal of the American Society of Clinical Oncology 2005;23(18):4079–4088.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975–980.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol: official journal of the American Society of Clinical Oncology 2012;30(26):3209–3216.
   PubMed Web of Science ®Google Scholar
• Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006;6(4):283–294.
   PubMed Web of Science ®Google Scholar
• Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology 2011;2011:96–103.
   Google Scholar
• Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 2012;24(6):643–649.
   PubMed Web of Science ®Google Scholar
• Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45(12):2365–2372.
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013;12(3):229–243.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol: official journal of the American Society of Clinical Oncology 2008;26(27):4497–503.
   PubMedGoogle Scholar
• Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848–1854.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101(12):4944–4951.
   PubMed Web of Science ®Google Scholar
• Messmer BT, Albesiano E, Efremov DG, Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200(4):519–525.
   PubMed Web of Science ®Google Scholar
• Allsup DJ, Kamiguti AS, Lin K, B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005;65(16):7328–7337.
   PubMed Web of Science ®Google Scholar
• Guarini A, Chiaretti S, Tavolaro S, BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112(3):782–792.
   PubMed Web of Science ®Google Scholar
• Mockridge CI, Potter KN, Wheatley I, Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007;109(10):4424–4431.
   PubMed Web of Science ®Google Scholar
• Krysov S, Dias S, Paterson A, Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012;119(1):170–179.
   Google Scholar
• Le Roy C, Deglesne PA, Chevallier N, The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood 2012;120(2):356–365.
   Google Scholar
• Paterson A, Mockridge CI, Adams JE, Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012;119(7):1726–1736.
   Google Scholar
• Cesano A, Perbellini O, Evensen E, Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. Haematologica 2013;98(4):626–634.
   Google Scholar
• Herman SE, Gordon AL, Hertlein E, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117(23):6287–6296.
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009;23(4):686–697.
   PubMed Web of Science ®Google Scholar
• Hewamana S, Alghazal S, Lin TT, The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111(9):4681–4689.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117(2):563–574.
   PubMed Web of Science ®Google Scholar
• Muzio M, Apollonio B, Scielzo C, Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008;112(1):188–195.
   PubMed Web of Science ®Google Scholar
• Duhren-von Minden M, Ubelhart R, Schneider D, Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489(7415):309–312.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 2009;94(6):752–756.
   PubMed Web of Science ®Google Scholar
• Ferretti E, Bertolotto M, Deaglio S, A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia 2011;25(8):1268–1277.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119(5):1182–1189.
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113(13):3050–3058.
   PubMed Web of Science ®Google Scholar
• Sivina M, Hartmann E, Kipps TJ, CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117(5):1662–1669.
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Eldering E, van Oers MH, Kater AP. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leuk Res 2013;37:838–847.
   Google Scholar
• de Rooij MF, Kuil A, Geest CR, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119(11):2590–2594.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre S, The Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. Blood 2012;120(21): Abstract 189.
   Google Scholar
• Farooqui M, Aue G, Valdez J, Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death. Blood 2012;120(21): Abstract 2899.
   Google Scholar
• Brown JR, Sharman JP, Harb WA, Phase 1b trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL)and B-non-Hodgkin lymphoma (B-NHL). 48th annual meeting of the American Society of Clinical Oncology. Chicago: 2012 IL2012.
   Google Scholar
• Evans E, Ponader S, Karp R, Covalent inhibition of BTK with clinical development compound AVL-292 disrupts signaling that maintains the microenvironment necessary for chronic lymphocytic leukemia growth. Clin Lymphoma, Myeloma & Lekemia Suppl 2011;11(Suppl 2):S173–S174.
   Google Scholar
• Evans EK, Tester R, Aslanian S, Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 2013. PubMed PMID: 23709115 [Epub ahead of print].
   Google Scholar
• Tan SL, Liao C, Lucas MC, Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther 2013;138(2):294–309.
   PubMed Web of Science ®Google Scholar
• Smaill JB, Showalter HD, Zhou H, Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem 2001;44(3):429–440.
   Google Scholar
• Tsou HR, Overbeek-Klumpers EG, Hallett WA, Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 2005;48(4):1107–1131.
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007;2(1):58–61.
   Google Scholar
• Kukimoto-Niino M, Takagi T, Kaminishi T, Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D). PDBID: 2DYL.
   Google Scholar
• Serafimova IM, Pufall MA, Krishnan S, Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nature Chem Biol 2012;8(5):471–476.
   PubMed Web of Science ®Google Scholar
• Hill RJ, Bisconte A, Bradshaw JM, Discovery of a highly potent, selective reversible covalent inhibitor of JAK3 kinase. Arthritis Rheum 2012;64(10):S982-S.
   Google Scholar
• Di Paolo JA, Huang T, Balazs M, Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chem Biol 2011;7(1):41–50.
   PubMed Web of Science ®Google Scholar
• Xu D, Kim Y, Postelnek J, RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther 2012;341(1):90–103.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Coffey GP, Sinha U, Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012;26(7):1576–1583.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578–2585.
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340(2):350–359.
   PubMed Web of Science ®Google Scholar
• Spurgeon SE, Coffey G, Fletcher LB, The selective SYK inhibitor P505–15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther 2013;344(2):378–387.
   PubMed Web of Science ®Google Scholar
• Liddle J, Atkinson FL, Barker MD, Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg Med Chem Lett 2011;21(20):6188–6194.
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009;183(9):5673–5684.
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22(24):8580–8591.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297(5583):1031–1034.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118(13):3603–3612.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591–594.
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119(8):1897–900.
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd J, Flinn I, Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 {delta}, in patients with relapsed or refractory non-hodgkin lymphoma. Blood 2010;116(21):1777.
   Web of Science ®Google Scholar
• Furman R, Byrd J, Flinn I, Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2010;28(15_suppl): 3032.
   Google Scholar
• Flinn I, Byrd J, Furman R, Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol (Meeting Abstracts) 2009;27(15S): 3543.
   Google Scholar
• Brown JR, Furman RR, Flinn I, Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. J Clin Oncol: official journal of the American Society of Clinical Oncology 2013;31: (suppl; abstr 7003).
   Google Scholar
• O'Brien SM, Lamanna N, Kipps TJ, A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 2013;31: (suppl; abstr 7005).
   Google Scholar
• Flinn IW, Horwitz SM, Patel M, Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-Kinase-δ,γ, in patients with advanced hematologic malignancies. Blood 2012;120(21): Abstract 3663.
   Google Scholar
• Patel MR, Kahl BS, Horwitz SM, Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL. J Clin Oncol 2013;31: suppl; abstr 7070.
   Google Scholar
• Coutre S, Byrd J, Furman R, Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011;29(15 suppl):6631.
   Google Scholar
• O'Farrell M, Ventura R, Tai A, Preclinical characterization of PWT143, a novel selective and potent phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor with ex-vivo activity in hematologic malignancies. Blood 2012;120(21):2907.
   Google Scholar
• Friedman DR, Lanasa MC, Brander DM, Comparison of the PI3K-δ inhibitors TGR1202 and GS-1101 in inducing cytotoxicity and inhibiting phosphorylation of Akt in CLL cells in vitro. Blood 2012;120(121): Abstract 3914.
   Google Scholar
• Iyengar S, Clear A, Bodor C, P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121(12):2274–2284.
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008;111(7):3322–3330.
   Google Scholar
• Park CM, Bruncko M, Adickes J, Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008;51(21):6902–6915.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–496.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Seymour JS, Davids MS, Pagel JM, Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31 suppl;:(abstract 7018).
   Google Scholar
• Adams JE. Proteosome inhibitors in cancer therapy. Totowa, NJ: Humana Press; 2004.
   Google Scholar
• Duechler M, Shehata M, Schwarzmeier JD, Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005;19(2):260–267.
   PubMed Web of Science ®Google Scholar
• Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010;15(5–6):243–249.
   PubMed Web of Science ®Google Scholar
• Faderl S, Rai K, Gribben J, Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107(5):916–924.
   PubMed Web of Science ®Google Scholar
• Liu FT, Agrawal SG, Movasaghi Z, Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008;112(9):3835–3846.
   PubMed Web of Science ®Google Scholar
• Ruiz S, Krupnik Y, Keating M, The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5(7):1836–1843.
   Google Scholar
• Macherla VR, Mitchell SS, Manam RR, Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005;48(11):3684–3687.
   PubMed Web of Science ®Google Scholar
• Groll M, Kim KB, Kairies N, Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of alpha’,beta’-Epoxyketone proteasome inhibitors. J Am Chem Soc 2000;122:1237–1238.
   Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Can Res 2007;67(13):6383–6391.
   PubMed Web of Science ®Google Scholar
• Gupta SV, Hertlein E, Lu Y, The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kappaB response in chronic lymphocytic leukemia cells. Clin Cancer Res 2013;19(9):2406–2419.
   Web of Science ®Google Scholar
• Hertlein E, Wagner AJ, Jones J, 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010;116(1):45–53.
   Google Scholar
• Hong DS, Banerji U, Tavana B, Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013;39(4):375–387.
   PubMed Web of Science ®Google Scholar
• Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013;19(3):366–376.
   Google Scholar
• Whitesell L, Santagata S, Lin NU. Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med 2012;12(9):1108–1124.
   Google Scholar
• Elfiky A, Saif MW, Beeram M, BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 2008;26(Suppl):2503.
   Google Scholar
• Antosz H, Sajewicz J, Marzec-Kotarska B, Aberrant TIRAP and MyD88 expression in B-cell chronic lymphocytic leukemia. Blood Cells Mol Dis 2013;51(1):48–55.
   Google Scholar
• Ngo VN, Young RM, Schmitz R, Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio MT, Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144(4):507–516.
   PubMed Web of Science ®Google Scholar
• Lim K-H, Romero DL, Chaudhary D, IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma. Blood 2012;120: Abstract 62.
   Google Scholar